Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer

NCT05160857 is registered in ClinicalTrials.gov with Second Hospital of Shanxi Medical University as lead sponsor.

NCT NCT05160857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Efficacy and Safety of Hetropapa Ethanolamine Tablets in the Treatment of Thrombocytopenia Caused by Concurrent Radiotherapy and Chemotherapy in Cervical Cancer
Lead sponsor
Second Hospital of Shanxi Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2021
Completion date
December 31, 2023
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tumor chemotherapy-related thrombocytopenia